Literature DB >> 15477532

FDA-approved neurologic devices intended for use in infants, children, and adolescents.

Carlos Peña1, Kristen Bowsher, Joy Samuels-Reid.   

Abstract

The US Food and Drug Administration (FDA) has approved several applications for the marketing of neurologic devices. Nineteen high risk Class III medical devices were approved for the central and peripheral nervous system for marketing between 1994 and 2003, and almost half (n = 8) include indications for use in children as well as adults. On July 24, 2003, the FDA Center for Devices and Radiologic Health released for public comment a draft guidance document entitled "Premarket Assessment of Pediatric Medical Devices," which included in its objectives, the types of information needed to provide reasonable assurance of the safety and effectiveness of medical devices intended for use in children. The draft guidance document is also relevant to the types of information needed to promote the safe and effective development of neurologic devices. We review risk assessment and ways to reduce risk for neurologic devices intended for use in children. We also discuss the deep brain stimulator, the cochlear implant, and the CSF shunt, and considerations for minimizing risks associated with brain development, physical growth, surgery, and human factors.

Entities:  

Mesh:

Year:  2004        PMID: 15477532     DOI: 10.1212/01.wnl.0000140625.72730.33

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Layered nanocomposites from gold nanoparticles for neural prosthetic devices.

Authors:  Huanan Zhang; Jimmy Shih; Jian Zhu; Nicholas A Kotov
Journal:  Nano Lett       Date:  2012-06-26       Impact factor: 11.189

2.  Morphing electronics enable neuromodulation in growing tissue.

Authors:  Yuxin Liu; Jinxing Li; Shang Song; Jiheong Kang; Yuchi Tsao; Shucheng Chen; Vittorio Mottini; Kelly McConnell; Wenhui Xu; Yu-Qing Zheng; Jeffrey B-H Tok; Paul M George; Zhenan Bao
Journal:  Nat Biotechnol       Date:  2020-04-20       Impact factor: 54.908

3.  Management of neonatal hydrocephalus: feasibility of use and safety of two programmable (Sophy and Polaris) valves.

Authors:  Juan F Martínez-Lage; María-José Almagro; Isabel Sanchez Del Rincón; Miguel A Pérez-Espejo; Claudio Piqueras; Raúl Alfaro; Javier Ros de San Pedro
Journal:  Childs Nerv Syst       Date:  2007-10-09       Impact factor: 1.475

4.  Medical Devices and Adolescents: Points to Consider.

Authors:  Joy H Samuels-Reid; Judith U Cope
Journal:  JAMA Pediatr       Date:  2016-11-01       Impact factor: 16.193

Review 5.  Epidemiology and management of essential tremor in children.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.